Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.73
+0.31 (1.13%)
At close: Dec 5, 2025, 4:00 PM EST
28.00
+0.27 (0.97%)
After-hours: Dec 5, 2025, 7:59 PM EST
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Agios Pharmaceuticals stock have an average target of 32.13, with a low estimate of 20 and a high estimate of 48. The average target predicts an increase of 15.87% from the current stock price of 27.73.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +37.04% | Nov 26, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +15.40% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $37 → $20 | Hold | Maintains | $37 → $20 | -27.88% | Nov 21, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $57 → $28 | Buy → Hold | Downgrades | $57 → $28 | +0.97% | Nov 20, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $54 → $32 | Strong Buy | Maintains | $54 → $32 | +15.40% | Nov 20, 2025 |
Financial Forecast
Revenue This Year
46.99M
from 36.50M
Increased by 28.75%
Revenue Next Year
112.52M
from 46.99M
Increased by 139.45%
EPS This Year
-7.20
from 11.64
EPS Next Year
-6.89
from -7.20
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.9M | 200.6M | ||||
| Avg | 47.0M | 112.5M | ||||
| Low | 42.1M | 65.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 36.7% | 326.8% | ||||
| Avg | 28.7% | 139.5% | ||||
| Low | 15.5% | 39.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.86 | -5.06 | ||||
| Avg | -7.20 | -6.89 | ||||
| Low | -7.21 | -8.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.